DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

Information source: McGill University Health Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Intervention: Alendronate (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: McGill University Health Center

Official(s) and/or principal investigator(s):
Richard Kremer, MD PhD, Principal Investigator, Affiliation: McGill University Health Center

Overall contact:
Richard Kremer, MD PhD, Phone: 514-934-1934, Ext: 32857

Summary

To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture

Clinical Details

Official title: A Six Month Double-Blind, Placebo-Controlled Trial Followed by Six Month Open-Label Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Eligibility

Minimum age: 55 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: Male and Female aged > 55 Low trauma hip fracture up to 90 days Be willing to submit to periodic bone mineral density radiographic studies of the spine & 24 hr urine collection Written informed consent

-

Exclusion Criteria:

- Disorders known to affect bone metabolism Not taking bisphosphonates within last 6

months Drugs known to interfere with calcium metabolism within the lats 6 months prior to hip fracture serum calcium> 2. 65 mmol/L Treatment with any investigational drug within the last 30 days

Locations and Contacts

Richard Kremer, MD PhD, Phone: 514-934-1934, Ext: 32857

Mcgill University Health center, Montreal, Quebec H3A 1A1, Canada; Recruiting
Richard Kremer, MD PhD, Phone: 514-934-1934, Ext: 32857
Richard Kremer, MD PhD FRCP(c), Principal Investigator
Additional Information

Starting date: January 2003
Last updated: April 11, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017